Escolar Documentos
Profissional Documentos
Cultura Documentos
aditividade e potencialização
François Noël - Matéria publicada na Newsletter da SBFTE, em Março 2014
Referências:
1. ANVISA, Resolução - RDC Nº 210, de 2 de Setembro de 2004.
2. Sühnel J. Evaluation of synergism or antagonism for the combined action of antiviral
agents. Antiviral Res. 13: 23–39, 1990.
3.http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm317004.htm
(consultado em: 29/02/2014).
4. Neubig R.R., Spedding M., Kenakin T., Christopoulos C. International Union of
Pharmacology Committee on Receptor Nomenclature and Drug Classification.
XXXVIII. Update on Terms and Symbols in Quantitative Pharmacology. Pharmacol.
Rev. 55: 597–606, 2003.
5. Berenbaum M.C. What is synergism ? Pharmacol. Rev. 41: 93-141, 1989.
6. Tallarida R.J. Drug Synergism: Its Detection and Applications. J. Pharmacol. Ther.
298: 865–872, 2001.
7. Groten J.P., Feron V.J., Sühnel J. Toxicology of simple and complex mixtures.
Trends Pharmacol. Sci. 22: 316-322, 2001.
8. Chou T.C. Theoretical Basis, Experimental Design, and Computerized Simulation of
Synergism and Antagonism in Drug Combination Studies. Pharmacol. Rev. 58: 621–
681, 2006.
9. ANVISA, Guia para Registro de Novas Associações em Dose Fixa. 1ª edição,
2010.
10. Tallarida R.J. Revisiting the Isobole and Related Quantitative Methods for
Assessing Drug Synergism. J. Pharmacol. Exp. Ther. 342: 2–8, 2012.